PCSANM's Position on US Preventative Services Task Force Revised Guideline on Prostate Cancer Screening
However, while PCSANM is pleased with the “C” recommendation embodied in the guidelines, there are weaknesses and omissions. Why a “C” but only for men 55-69? Just because the retrospective studies to date have looked more at that age group than others ignores the fact that because prostate cancer is often slow-growing, one doesn’t see the benefits of screening sometimes for more than 10-15 years. Screening early means fewer chances of developing metastatic disease during those years, so why wait until 55 to start testing? We believe that a man’s first, baseline PSA should be around the age of 45, establishing risk and personalizing future follow up. That risk stratification is critical. PSA is just a data point; it is what you do with that information that is important.
Why does the USPSTF (that worries about over treatment if a man is diagnosed) not recommend genomic testing, MRI, liquid biopsies, and other indolent disease that might lead to active surveillance rather than treatment? Why stop testing at age 70 and classify that as a “D” recommendation? Both the American Cancer Society and National Comprehensive Cancer Network talk about testing for men with at least a ten-year life expectancy– that should be the criterion, not an arbitrary age marker. And veterans, especially those who were exposed to Agent Orange, should be included in the “higher risk” population for earlier testing, along with African-American men and men with a positive family history.
US Preventative Services Task Force (USPSTF) Revised Guideline on Prostate Cancer Screening
US Preventive Services Task Force "C" Grade for Prostate Cancer Testing
Offer or provide this service for selected patients depending on individual circumstances.
An AI tool was able to detect prostate cancer on tissues slides with more accuracy than human clinicians
The efficacy of CPIs in prostate cancer has been disappointing.
Use of genetic testing to stratify risk and guide screening and management continues to gain momentum.
Delayed luteinizing hormone-releasing hormone (LHRH) agonist dosing doubles castration levels in prostate cancer
Administration of LHRH agonists was significantly more delayed in clinical practice than in pivotal clinical trials
Read findings recently published in European Urology.
PET/CT imaging potentially useful in evaluating metastatic castrate-resistant prostate cancer (mCRPC) treatment
Read this Renal & Urology News article.
These data will help to optimize care for men.
More men than previously thought suffer from erectile dysfunction and urinary incontinence after prostate cancer treatment
(AKA the 14th installment in a finite series), by Mark Moyad, MD, MPH
Variant could aid in treatment and screening decisions